Welcome to the e-CCO Library!

DOP065: Use of chromoendoscopy versus white light endoscopy for colorectal cancer surveillance in inflammatory bowel disease patients with primary sclerosing cholangitis; a six year experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hartery K., Williamson K., Chapman R., Atkinson N., East J.

Created: Wednesday, 20 February 2019, 10:36 AM
DOP066: Developing a core outcome set for fistulising perianal Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Sahnan1*, P.J. Tozer1, S.O. Adegbola1, M.J. Lee2, N. Heywood3, A.G.K. McNair4, D. Hind5, N. Yassin6, A.J. Lobo7, S.R. Brown2, S. Sebastian8, R.K. Phillips1, P.F. Lung9, O.D. Faiz1, K. Crook10, S. Blackwell11, A. Verjee12, A.L. Hart13, N.S. Fearnhead14

Created: Thursday, 21 February 2019, 9:14 AM
DOP066: Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Strik*1, G. van den Brink1, C. Ponsioen1, R. Mathot2, M. Löwenberg1, G. D’Haens1

Created: Friday, 22 February 2019, 9:49 AM
DOP066: Strict surveillance colonoscopy should be performed for the ulcerative colitis patients who underwent ileorectal anastomosis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Anzai H., Hata K., Ishihara S., Kishikawa J., Murono K., Kaneko M., Sasaki K., Yasuda K., Otani K., Nishikawa T., Tanaka T., Kiyomatsu T., Kawai K., Nozawa H., Watanabe T.

Created: Wednesday, 20 February 2019, 10:36 AM
DOP067: Factors influencing infliximab and adalimumab antibody formation and 6 month retrospective follow-up in a tertiary IBD centre
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. Digby-Bell*1, B. Warner1, E. Johnston1, N. Unsworth2, Z. Arkir2, J. Sanderson1, P. Irving1

Created: Friday, 22 February 2019, 9:49 AM
DOP067: Risk of malignant and non-malignant complications of the rectal stump in patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bogaerts J.*1, Ten Hove J.R.1, Laclé M.M.2, Meij V.3, Oldenburg B.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP067: Treatment discontinuation, flares and hospitalisations among biologic-naïve patients with IBD over the first year of treatment: a comparative effectiveness study of vedolizumab vs. infliximab
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Raluy-Callado1, A. Berger2, J.M. Khalid3, H. Patel3*

Created: Thursday, 21 February 2019, 9:14 AM
DOP068: Crohn’s disease decision aid leads to more patients choosing combination therapy in a cluster randomised controlled trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

C.A. Siegel1*, K.D. Thompson1, L.S. Siegel2, T. MacKenzie3, M.C. Dubinsky4

Created: Thursday, 21 February 2019, 9:14 AM
DOP068: Insufficient infliximab exposure predisposes to immunogenicity and enhanced clearance of infliximab in IBD
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. F. Brandse*1, D. R. Mould2, Y. K. Ashruf1, O. Smeekes1, S. Kuin1, A. Strik1, G.R. van den Brink1, G. R. D’Haens1

Created: Friday, 22 February 2019, 9:49 AM
DOP068: The virtual electronic chromoendoscopy score in ulcerative colitis exhibits very good inter-rater agreement in scoring mucosal and vascular changes after computerised module training: a study across academic and community practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Trivedi P.*1,2,3,4, Hodson J.3, Bhala N.4, Cooney R.4, Boulton R.4, Gui X.5, Iqbal T.4, Li K.-k.6, Mumtaz S.7, Pathmakanthan S.4, Quraishi M.N.4, Sagar V.M.1, Shah A.7, Sharma N.8, Siau K.7, Smith S.4, Ward S.9, Widlak M.M.10,11, Ghosh S.3,4, Iacucci M.3,4

Created: Wednesday, 20 February 2019, 10:36 AM
DOP069: Dose optimisation using drug and antibody levels can benefit 50% patients prescribed anti-TNF therapy compared with empiric dose adjustment
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Harrow*1, C. Skinner1, T. Hoque1, A. Ibarra1, J. Lindsay1, 2

Created: Friday, 22 February 2019, 9:49 AM
DOP069: Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: A randomised control trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Atreja1*, E. Otobo1, E. Szigethy2, H. Shroff1, H. Chang1, L. Keefer1, J. Rogers1, T. Ullman1, J.F. Marion1, B. Cohen1, E. Maser1, S. Itzkowitz1, J.-F. Colombel1, B. Sands1

Created: Thursday, 21 February 2019, 9:14 AM
DOP069: Natural history of dysplasia and colorectal cancer in IBD patients in Belgium tertiary care centers
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Cremer A.*1, Liefferinckx C.1, De Vos M.2, Rahier J.-F.3, Baert F.4, Moreels T.5, Macken E.5, Louis E.6, Devière J.1, Van Gossum A.1, Vermeire S.7, Franchimont D.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP06: Antibiotics as a risk factor for older onset IBD: A population-based cohort study
Year: 2022
Source: ECCO'22
Authors: Faye, A.(1);Allin, K.(2);Iversen, A.(2);Agrawal, M.(3);Faith, J.(4);Jean-Frederic , C.(3);Jess, T.(2);
Created: Friday, 11 February 2022, 3:52 PM
DOP06: Deep characterization of IL-23 pathway in different gut segments and associated plasma biomarkers in inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cairns, J.(1)*;Monkley, S.(2);Tian, S.(3);Angermann, B.(2);Liu, Z.(4);Öberg, L.(5);Muthas, D.(2);Cabrera, C.(6);Rapsomaniki, E.(7);Fernández Llaneza, D.(7);Olsson, M.(8);Paraskos, J.(9);Ellison, G.(10);Khan, E.(11);Duncan, E.A.(12);Neisen, J.(13);Gehrmann, U.(5);Chamberlain, C.(3);
Created: Friday, 14 July 2023, 10:43 AM
DOP06: Dynamic shifts in the balance of gut homing Treg and Th17 cells play a critical role in ulcerative colitis and may predict response to vedolizumab therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Hermangild Kottoor*1, Z. Kassam1, P. Pavlidis1,2, E. Alberts1, H. Ibraheim1,2, L. Constable1, J. Digby-Bell1, D. Warren2, S. Odukwe2, M. Samaan2, P. Irving2, J. Sanderson2, N. Powell1,2

Created: Friday, 22 February 2019, 9:41 AM
DOP06: Histologic activity in Ulcerative Colitis patients achieving endoscopic healing is associated with higher rate of relapse and a distinct mucosal microbial and transcriptional profile
Year: 2021
Source: ECCO'21 Virtual
Authors: Hernandez-Rocha, C.(1);Turpin, W.(2);Nayeri, S.(3);Borowski, K.(3);Stempak, J.(3);Conner, J.(4);Silverberg, M.S.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP07 Long-term results of 4.5 years of faecal microbiota transplantation for treatment of refractory ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Uygun1, M.F. Karakaya1, H. Erdal1, G. Celebi1, Y.S. Sakin1, C. Artuk2, K. Ozturk1, M. Gulsen1

Created: Thursday, 30 January 2020, 10:12 AM
DOP070: Development and pilot of an index to identify young people with inflammatory bowel disease at risk of psychological morbidity
Year: 2018
Source: ECCO '18 Vienna
Authors:

R.T. Lees1*, A.J. Brooks1, G. Rowse2, P. Narula3, P. Norman4, A.J. Lobo1

Created: Thursday, 21 February 2019, 9:14 AM
DOP070: Endoscopic response to induction therapy with TNF inhibitors is the best predictor of long term mucosal healing in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Alfaro I.*1, Masamunt M.1, Planell N.2, Lόpez-García A.1, Castro J.1, Gallego M.1, Barastegui R.1, Giner A.1, Vara A.1, Salas A.2, Ricart E.1, Panés J.1, Ordás I.1

Created: Wednesday, 20 February 2019, 10:36 AM